We are incredibly excited to announce that we have launched a spin-out, Biotech Tricopharming Research (or Tricopharming for short) in order to produce and commercialize Artennua, our improved version of the Artemisia annua medicinal plant.
The spin-out derives from our R&D department, which used Tricopharming technology, or agricultural biopharming applied to plant trichomes, to produce and commercialize therapeutically valuable molecules. Dr Luís Matías Hernández, then principal investigator at Sequentia, now CEO of the new company, was able to improve the concentration of artemisinin in planta; the foliar biomass (therefore obtaining more trichomes to produce artemisinin); and the annual production of the plant using completely natural and sustainable methods in the lab. We named this optimized version Artepharming at first, and then, Artennua.
Being awarded the CDTI grant within the NEOTEC program enabled us to start pilot production in the Canary Islands in 2017, and now, following positive results in the field, cultivation has started and we are iniating Beta-testing with several companies.
For this reason, we decided to create a new entity for the commercialization of Artennua, as well as other future products from our R&D activities.
We are confident of the therapeutic value of Artennua and its potential in the market, which includes (but is not limited to) industries like nutraceuticals, natural cosmetics and animal health.
Read the press release for the full details and visit our associated websites and social media channels to stay up to date with all our news!!